NDLI: Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.

Please wait, while we are loading the content...

Prevalence of antibodies against Chlamydia trachomatis and incidence of C. trachomatis-induced reactive arthritis in an early arthritis series in Finland in 2000.

Reproductive health in women with systemic lupus erythematosus compared to population controls.

Functional bowel symptoms and GnRH antibodies: common findings in patients with primary Sjögren's syndrome but not in systemic sclerosis.

Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis.

Frequency of successful intra-articular puncture of the sternoclavicular joint: a cadaver study.

Potential effects of a national consensus statement on optimal treatment of early rheumatoid arthritis in Ontario.

Circulating TNFRI and TNFRII levels correlated with the disease activity score (DAS28) in rheumatoid arthritis.

Recurrent tonsillitis and tonsillectomy in juvenile idiopathic arthritis.

Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.

Coronary atherosclerosis using computed tomography coronary angiography in patients with systemic sclerosis.

Comparison of three rheumatoid arthritis disease activity scores in clinical routine.

Patient experiences of rehabilitation in rheumatology: association with process and outcome.

Health status and perception of pain: a comparative study between female patients with hand osteoarthritis and rheumatoid arthritis.

Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.

Year: 2009 Volume: 38 Issue: 4

Year: 2009 Volume: 38 Issue: 3

Year: 2009 Volume: 38 Issue: 2

Year: 2009 Volume: 38 Issue: 1

Year: 2008 Volume: 37

Year: 1998 Volume: 27

Year: 1987 Volume: 16

Year: 1980 Volume: 9

Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Exarchou, S. A. Voulgari, P. V. Markatseli, T. E. Zioga, A. Drosos, A. A.
Description	Country affiliation: Greece Author Affiliation: Exarchou SA ( Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.)
Abstract	OBJECTIVE: To describe immune-mediated skin lesion (IMSL) development in patients during anti-tumour necrosis factor (TNF) therapy. METHODS: Two hundred and fifty-two patients with rheumatoid arthritis (RA) and 183 with spondyloarthropathies (SpA) treated with anti-TNF inhibitors were analysed to identify IMSLs. RESULTS: Of the 252 patients with RA (146 treated with infliximab, 72 with adalimumab, and 34 with etanercept), 32 developed IMSLs. Eleven patients developed psoriatic skin lesions, 10 presented with granuloma annulare (GA), five had skin vasculitis, two alopecia areata, two discoid lupus erythematosus, one lichenoid eruption (lichen planus), and one vitiligo. Of the 183 patients with SpA (138 treated with infliximab, 37 with etanercept, and eight with adalimumab), 10 cases with IMSLs were identified. All were treated with infliximab. More specifically, six patients with ankylosing spondylitis (AS) developed psoriatic skin lesions, one developed GA, one lichen planus, and one alopecia areata. In addition, one patient with psoriatic arthritis (PsA) developed skin vasculitis. The occurrence of these IMSLs ranged from 3 to 36 months with a median of 20 months. Of all the patients with IMSL development, two with psoriatic skin lesions, two with GA, and one with vasculitis stopped anti-TNF therapy because of the extent and severity of the skin lesions. CONCLUSIONS: Our results on patients treated with TNF antagonists strongly support a link between TNF inhibition and IMSL development. Although these clinical complications are rare, clinicians should be aware of their occurrence and should recognize them.
File Format	HTM / HTML
ISSN	03009742
e-ISSN	15027732
Journal	Scandinavian Journal of Rheumatology
Issue Number	5
Volume Number	38
Language	English
Publisher	Taylor & Francis
Publisher Date	2009-01-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Rheumatology Antibodies, Monoclonal Adverse Effects Antirheumatic Agents Arthritis, Rheumatoid Drug Therapy Immunoglobulin G Skin Diseases Chemically Induced Spondylarthropathies Chi-square Distribution Etanercept Infliximab Receptors, Tumor Necrosis Factor Severity Of Illness Index Tumor Necrosis Factor-alpha Antagonists & Inhibitors
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Immunology Rheumatology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

Treating rheumatoid arthritis with tumour necrosis factor alpha blockade.

Anti-TNF therapy.

Metabolic profiling predicts response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis.

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.

Etanercept decreases synovial expression of tumour necrosis factor- and lymphotoxin- in rheumatoid arthritis.

Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists.

Non-length-dependent and length-dependent small-fiber neuropathies associated with tumor necrosis factor (TNF)-inhibitor therapy in patients with rheumatoid arthritis: expanding the spectrum of neurological disease associated with TNF-inhibitors.

Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.

Similar Documents

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

Treating rheumatoid arthritis with tumour necrosis factor alpha blockade.

Anti-TNF therapy.

Metabolic profiling predicts response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis.

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.

Etanercept decreases synovial expression of tumour necrosis factor- and lymphotoxin- in rheumatoid arthritis.

Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists.

Non-length-dependent and length-dependent small-fiber neuropathies associated with tumor necrosis factor (TNF)-inhibitor therapy in patients with rheumatoid arthritis: expanding the spectrum of neurological disease associated with TNF-inhibitors.

Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.